Company Information

  

Address: 800 THIRD AVENUE
11TH FLOOR 
City: NEW YORK 
State: NY 
Zip Code: 10022 
Telephone: (212) 682-8452 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Ohr Pharmaceutical, Inc. ("we," "us," "our," "Ohr," or the "Company") is a pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Our development pipeline consists of several programs and indications at various stages of development. Our lead clinical asset, topical Squalamine (also known as squalamine lactate ophthalmic solution, 0.2%, or OHR-102), is a novel therapeutic product which could provide a non-invasive therapy to improve vision outcomes beyond that achieved with current standard of care, without requiring multiple injections per office visit. We are conducting a Phase 3 registration program evaluating Squalamine in combination with Lucentis┬« injections for the treatment of wet-AMD.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.66NAN/E
03/2017-0.88NAN/E
12/2016-0.83NAN/E
09/2016-0.82NAN/E
06/2016-0.74NAN/E
03/2016-0.61NAN/E
12/2015-0.56NAN/E
09/2015-0.54NAN/E

Key Financial Ratios and Statistics

FYE: 09/30

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.15
Net Inc/Total Assets-0.88Total Liab/Inv Cap0.18
Net Inc/Inv Cap-1.04Total Liab/Comm Equity0.04
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/Equity0.00
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/Equity0.00
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio2.96
Inventory TurnoverNACurrent Ratio2.96
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.33 1.40 1.75 1.81
Operating Income -3.86 -7.69 -6.98 -6.81
Interest Exp NA NA NA NA
Pretax Income -3.90 -7.69 -6.98 -6.64
Other Income 0.01 0.00 0.00 0.17
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -3.90 -7.69 -6.98 -6.64

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 18.08 9.52 13.49 12.55
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 18.52 10.09 13.86 13.29
Net Property, Plant & Equipment 0.08 0.17 0.19 0.20
Total Assets 33.72 25.67 29.73 29.45
Liabilities        
Accounts Payable 5.44 6.78 3.89 4.39
Debt in Current Liabilities 0.16 0.26 0.00 0.09
Total Current Liabilities 5.59 7.04 3.89 4.48
Long-Term Debt NA NA NA NA
Total Liabilities 5.74 7.04 3.89 4.48
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.00 0.00 0.00
Retained Earnings -102.84 -98.94 -91.25 -84.28
Treasury Stock NA NA NA NA
Total Stockholders' Equity 27.97 18.62 25.84 24.96
Total Liabilities and Stockholders' Equity 33.72 25.67 29.73 29.45

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -4.12 -3.97 -5.93 -5.03
Net Cash Provided by Investing Activities 0.09 0.00 -0.00 -0.00
Net Cash Provided by Financing Activities 12.59 0.00 6.88 -0.04

Annual Summary Data (Millions)

Year Sales Net Income EPS
09/20120.00-1.45--
09/20130.00-5.65-0.30
09/20140.00-9.13-0.41
09/20150.00-15.20-0.54
09/20160.00-25.77-0.82
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17473,9467.02




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.